Blog

Immediate Subsequent lines of therapy after T-DXd in Metastatic Breast Cancer – Dana-Farber’s Breast Oncology Center

Metastatic Breast Cancer/LinkedIn

Dec 14, 2024, 06:34

Immediate Subsequent lines of therapy after T-DXd in Metastatic Breast Cancer – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X:

“SABCS24 POSTER SESSION | P1-08-08 |

Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with Metastatic Breast Cancer (MBC) – retrospective study from the nationwide Flatiron database.”

Immediate Subsequent lines of therapy after T-DXd in Metastatic Breast Cancer - Dana-Farber’s Breast Oncology Center

breast oncology cancer Center Dana-Farber’s Breast Oncology Center fight against cancer Global fight against cancer MBC metastatic breast cancer OncoDaily Oncology SABCS24 T-Dxd Trastuzumab deruxtecan

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage